参考文献/References:
[1] Alter MJ.Epidemiology of hepatitis C virus infection[J].World J Gastroenterol,2007,13(17):2436-2441.
[2] Antonelli A,Ferri C,Fallahi P,et al.Thyroid disorders in chronic hepatitis C virus infection[J].Thyroid,2006,16(6):563-572. DOI:10.1089/thy.2006.16.563.
[3] Tran A,Quaranta JF,Beusnel C,et al.Hepatitis C virus and Hashimoto's thyroiditis[J].Eur J Med,1992,1(2):116-118.
[4] Duclos-Vallée JC,Johanet C,Trinchet JC,et al.High prevalence of serum antibodies to hepatitis C virus in patients with Hashimoto's thyroiditis[J].BMJ,1994,309(6958):846-847.
[5] Antonelli A,Ferri C,Pampana A,et al.Thyroid disorders in chronic hepatitis C[J].Am J Med,2004,117(1):10-13.DOI:10.1016/j.amjmed.2004.01.023.
[6] Giordano TP,Henderson L,Landgren O,et al.Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus[J].JAMA,2007,297(18):2010-2017.DOI:10.1001/jama.297.18.2010.
[7] Ganne-Carrie N,Medini A,Coderc E,et al.Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study[J].J Autoimmun,2000,14(2):189-193.DOI:10.1006/jaut.1999.0360.
[8] Indolfi G,Stagi S,Bartolini E,et al.Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection[J].Clin Endocrinol(Oxf),2008,68(1):117-121. DOI:10.1111/j.1365-2265.2007.03009.x.
[9] Shen Y,Wang XL,Xie JP,et al.Thyroid disturbance in patients with chronic hepatitis C infection: a systematic review and meta-analysis[J].J Gastrointestin Liver Dis,2016,25(2):227-234.DOI:10.15403/jgld.2014.1121.252.chc.
[10] Yang R,Shan Z,Li Y,et al.Prevalence of thyroid autoantibodies in hepatitis C and hepatitis B infection in China[J].Intern Med,2011,50(8):811-815.
[11] Tomer Y,Davies TF.Infection, thyroid disease, and autoimmunity[J].Endocr Rev,1993,14(1):107-120.DOI:10.1210/edrv-14-1-107.
[12] Akeno N,Blackard JT,Tomer Y.HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity[J].J Autoimmun,2008,31(4):339-344.DOI:10.1016/j.jaut.2008.08.001.
[13] Martocchia A,Falaschi P.Amino acid sequence homologies between HCV polyprotein and thyroid antigens[J].Intern Emerg Med,2007,2(1):65-67. DOI:10.1007/s11739-007-0018-x.
[14] Pastore F,Martocchia A,Stefanelli M,et al.Hepatitis C virus infection and thyroid autoimmune disorders: a model of interactions between the host and the environment[J].World J Hepatol,2016,8(2):83-91.DOI:10.4254/wjh.v8.i2.83.
[15] Tomer Y,Villanueva R.Hepatitis C and thyroid autoimmunity: is there a link?[J].Am J Med,2004,117(1):60-61.DOI:10.1016/j.amjmed.2004.04.004.
[16] Tomer Y,Blackard JT,Akeno N.Interferon alpha treatment and thyroid dysfunction[J].Endocrinol Metab Clin North Am,2007,36(4):1051-1066; x-xi.DOI:10.1016/j.ecl.2007.07.001.
[17] Mihm S,Schweyer S,Ramadori G.Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B[J].J Med Virol,2003,70(4):562-570.DOI:10.1002/jmv.10431.
[18] Matskevich AA,Strayer DS. Exploiting hepatitis C virus activation of NFkappaB to deliver HCV-responsive expression of interferons alpha and gamma[J].Gene Ther,2003,10(22):1861-1873.DOI:10.1038/sj.gt.3302091.
[19] Murata M,Nabeshima S,Maeda N,et al.Increased frequency of IFN-gamma-producing peripheral CD8+ T cells with memory-phenotype in patients with chronic hepatitis C[J].J Med Virol,2002,67(2):162-170.DOI:10.1002/jmv.2205.
[20] Romagnani P,Rotondi M,Lazzeri E,et al.Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease[J]. Am J Pathol,2002,161(1):195-206. DOI:10.1016/S0002-9440(10)64171-5.
[21] Zhang RW,Shao CP,Huo N,et al.Thyroid dysfunction in Chinese hepatitis C patients: prevalence and correlation with TPOAb and CXCL10[J].World J Gastroenterol,2015,21(33):9765-9773.DOI:10.3748/wjg.v21.i33.9765.
[22] Antonelli A,Rotondi M,Fallahi P,et al.Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter[J].J Clin Endocrinol Metab,2007,92(4):1485-1490.DOI:10.1210/jc.2006-1571.
[23] Antonelli A,Ferri C,Fallahi P.Thyroid cancer in patients with hepatitis C infection[J].JAMA,1999,281(17):1588.
[24] Montella M,Crispo A,de Bellis G,et al.HCV and cancer: a case-control study in a high-endemic area[J].Liver,2001,21(5):335-341.
[25] Antonelli A,Ferri C,Fallahi P,et al.Thyroid cancer in HCV-related mixed cryoglobulinemia patients[J].Clin Exp Rheumatol,2002,20(5):693-696.
[26] Wang P,Jing Z,Liu C,et al.Hepatitis C virus infection and risk of thyroid cancer: a systematic review and meta-analysis[J].Arab J Gastroenterol,2017,18(1):1-5.DOI:10.1016/j.ajg.2017.01.003.
[27] Prummel MF,Laurberg P.Interferon-alpha and autoimmune thyroid disease[J].Thyroid,2003,13(6):547-551.DOI:10.1089/105072503322238809.
[28] Antonelli A,Ferri C,Fallahi P,et al.Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study[J].Thyroid,2007,17(5):447-451.DOI:10.1089/thy.2006.0194.
相似文献/References:
[1]陈宁,朱云娟,陈慧,等.TSHR胞外区中间段在BALB/c小鼠体内的免疫原性研究[J].国际内分泌代谢杂志,2007,(04):267.
[2]张蓉,俞立波,李连喜.组蛋白修饰与甲状腺癌[J].国际内分泌代谢杂志,2014,(05):348.[doi:10.3760/cma.j.issn.1673-4157.2014.05.017]
Zhang Rong,Yu Libo,Li Lianxi..Histone modification and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2014,(02):348.[doi:10.3760/cma.j.issn.1673-4157.2014.05.017]
[3]李兴佳,徐书杭,刘超.雌激素及其受体与甲状腺癌的关系[J].国际内分泌代谢杂志,2016,36(04):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
Li Xingjia,Xu Shuhang,Liu Chao.Relationship between estrogen, its receptors and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2016,36(02):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
[4]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(02):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[5]郑仁东,刘超.STAT3与甲状腺肿瘤[J].国际内分泌代谢杂志,2017,37(05):345.
Zheng Rendong,Liu Chao..STAT3 and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2017,37(02):345.
[6]孟祥慧 徐书杭 陈国芳 刘超.二甲双胍在甲状腺癌防治中的作用[J].国际内分泌代谢杂志,2018,38(04):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
Meng Xianghui*,Xu Shuhang,Chen Guofang,et al.Role of metformin in prevention and treatment of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2018,38(02):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
[7]曹星月 武晓泓.基因拷贝数异常在甲状腺癌诊断和预后判断中的
应用进展[J].国际内分泌代谢杂志,2019,39(01):29.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
Cao Xingyue,Wu Xiaohong.Progress in the application of gene copy number variations in diagnosis and prognosis of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(02):29.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
[8]张玉洁 孟召伟 章明放 宋丽丽 李宁.甲状腺疾病的代谢组学研究现状[J].国际内分泌代谢杂志,2019,39(03):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
Zhang Yujie,Meng Zhaowei,Zhang Mingfang,et al.Research status of metabolomics in thyroid diseases[J].International Journal of Endocrinology and Metabolism,2019,39(02):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
[9]田勍,洪天配.甲状腺结节诊治过程中的难点与应对[J].国际内分泌代谢杂志,2021,41(06):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
Tian Qing,Hong Tianpei..Difficulties and countermeasures in the diagnosis and treatment of thyroid nodules[J].International Journal of Endocrinology and Metabolism,2021,41(02):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
[10]张雅,相萍萍,徐书杭,等.经皮无水乙醇注射治疗甲状腺结节:老方法的新认识[J].国际内分泌代谢杂志,2022,42(06):469.[doi:10.3760/cma.j.cn121383-20210926-09075]
Zhang Ya,Xiang Pingping,Xu Shuhang,et al.Percutaneous ethanol ablation for thyroid nodules: new perspectives on an old paradigm[J].International Journal of Endocrinology and Metabolism,2022,42(02):469.[doi:10.3760/cma.j.cn121383-20210926-09075]